Group 1: Cloud Intelligence Technology - Yunzhisheng officially listed on the Hong Kong Stock Exchange on June 30, 2025, with the stock code "9678," becoming the first AGI stock in Hong Kong [2][5] - The company launched its first large language model, UniCore, based on BERT, and later developed the Shanhai model with 60 billion parameters, achieving significant performance in various evaluations [3][4] - Yunzhisheng's revenue from 2022 to 2024 was 601 million, 727 million, and 939 million CNY, with a compound annual growth rate (CAGR) of 25% [4] Group 2: Ophthalmic Biotechnology - Bokan Shiyun officially listed on the Hong Kong Stock Exchange on July 3, 2025, with the stock code "2592" [6] - The company focuses on developing differentiated drugs for major eye diseases using proprietary technology platforms [6] - Bokan Shiyun's core product CBT-001 is undergoing Phase III clinical trials in the US and China, aiming to provide non-invasive treatment for pterygium [6][7] Group 3: GPU Technology - Moore Threads submitted its prospectus for the Sci-Tech Innovation Board on June 30, 2025, focusing on self-developed GPUs for high-performance computing [8][9] - The company has achieved significant breakthroughs in GPU technology, with products nearing international advanced levels [10] - Revenue from 2022 to 2024 was 46 million, 124 million, and 438 million CNY, with a CAGR exceeding 200% [11] Group 4: Healthcare Payment Solutions - Meixin Health submitted its prospectus for the Hong Kong Stock Exchange on June 30, 2025, becoming the largest multi-payment platform in China [14][15] - The company has saved patients approximately 6.7 billion CNY in out-of-pocket expenses by the end of 2024 [14] - Revenue from 2022 to 2024 was 1.069 billion, 1.255 billion, and 2.035 billion CNY, with a gross profit margin of 31.1%, 36.8%, and 35.8% respectively [16] Group 5: Industrial Robotics - Yifei Technology submitted its prospectus for the Hong Kong Stock Exchange on June 30, 2025, focusing on industrial robots for the light industry [19][20] - The company is ranked fifth among domestic suppliers of industrial robots and related solutions in China [20] - As of June 21, 2025, Yifei Technology has over 400 million CNY in hand orders [22] Group 6: AI in Medical Imaging - Deshi Biotechnology submitted its prospectus for the Hong Kong Stock Exchange on June 29, 2025, focusing on AI in medical imaging [42] - The company's iMedImageTM model supports 19 types of medical imaging modalities, covering over 90% of clinical scenarios [43] - Revenue for 2023 and 2024 was 52.84 million and 70.35 million CNY, with gross profit margins of 71.0% and 65.5% respectively [48] Group 7: Antibody-Drug Conjugates - BlissBio Inc. submitted its prospectus for the Hong Kong Stock Exchange on June 29, 2025, focusing on next-generation ADCs for cancer treatment [50][51] - The company has four ADC candidates in clinical stages, with BB-1701 being the leading candidate for treating HER2-positive breast cancer [51][53] Group 8: Integrated Elderly Care Services - Puxiang Health submitted its prospectus for the Hong Kong Stock Exchange on June 30, 2025, focusing on integrated medical and elderly care services [55] - The company is ranked second among integrated elderly care service providers in North China by revenue [56] - Revenue from 2022 to 2024 was 255 million, 422 million, and 500 million CNY [57]

Group 1 - Suzhou Gaoxin District's company BoKangShiYun Biopharmaceutical Technology (Suzhou) Co., Ltd. was listed on the Hong Kong Stock Exchange on July 3, with an issue price of HKD 10.1 and a total fundraising amount of HKD 612 million [1] - BoKangShiYun is an innovative clinical-stage ophthalmic biotechnology company focused on developing novel and differentiated therapies, with a pipeline of 7 candidate drugs targeting major diseases of the eye [1] - The core product CBT-001, a global first for treating pterygium eye surface disease, is currently in Phase III clinical trials, while CBT-009 for treating juvenile myopia is expected to enter Phase III trials by the end of 2025 [1] Group 2 - The Gaoxin District has gathered over 1,400 enterprises related to the medical device and health industry, with a production value exceeding 50 billion and an annual growth rate of over 30% [2] - The district aims to continue fostering enterprise cultivation and listing as a key driver for high-quality development, enhancing the service system for the entire lifecycle of enterprises [2]

Core Viewpoint - The article highlights the successful IPO of Bokan Vision Pharmaceutical Co., Ltd., which is positioned to become a leader in the ophthalmic biotechnology sector with innovative drug candidates like CBT-001 and CBT-009 aimed at addressing unmet medical needs in eye diseases [3][5][9]. Company Overview - Bokan Vision is a biotechnology company focused on developing differentiated drugs for major eye diseases using proprietary technology platforms, including small molecule multi-kinase inhibitors and antibody-drug conjugates [6]. - The company has launched two key drug candidates: CBT-001 for treating pterygium and CBT-004 for treating vascularized eyelid lesions, both of which are expected to be the first of their kind globally [6][9]. IPO Details - On July 3, Bokan Vision officially listed on the Hong Kong Stock Exchange under the stock code "2592," raising approximately HKD 522 million through the issuance of 60.582 million shares, with a public offering oversubscribed by 78.78 times [3][4]. - The company attracted two cornerstone investors, raising a total of USD 22.8 million (approximately HKD 179 million) [3]. Clinical Development - CBT-001 has initiated Phase III clinical trials in the U.S. and China, with the potential to provide non-invasive treatment options for pterygium, thereby reducing the need for surgical intervention [8][9]. - CBT-009, aimed at treating myopia in adolescents, completed Phase I/II trials and is set to submit an IND application to the FDA in July 2024 [8][9]. Market Potential - The ophthalmic drug market is projected to exceed USD 10 billion in China, indicating significant growth potential in the sector [9]. - The demand for new ophthalmic drugs is increasing due to slow development progress in the field, making it a promising area for investment and innovation [9].

Group 1: CaoCao Inc. (曹操出行) - CaoCao Inc. officially listed on the Hong Kong Stock Exchange on June 25, 2025, with the stock code "2643" [3] - Established in 2015, CaoCao has become one of the largest ride-hailing platforms in China, covering 136 cities as of December 31, 2024, with 85 new cities added in 2024 [3] - The total Gross Transaction Value (GTV) for 2023 and 2024 was 12.2 billion yuan and 17 billion yuan, representing growth rates of 37.5% and 38.8% respectively [3] - In Q1 2024, CaoCao's GTV reached 4.8 billion yuan, a 54.9% increase year-on-year, with order volume growing by 51.8% [3][5] - The company operates a fleet of over 34,000 customized vehicles, making it the largest fleet in China according to Frost & Sullivan [4] - CaoCao launched an autonomous driving platform in February 2024 and plans to introduce L4-level Robotaxi models by the end of 2026 [4] Group 2: SAINT BELLA Inc. (圣贝拉) - SAINT BELLA Inc. listed on the Hong Kong Stock Exchange on June 26, 2025, with the stock code "2508" [7] - The company operates 96 high-end postpartum care centers under various brands, with significant growth in self-operated and managed centers from 2022 to 2024 [7] - SAINT BELLA is recognized as the largest postpartum care and recovery group in China and Asia, with a market share of approximately 1.2% in 2024 [7] Group 3: BoKang Vision Cloud (拨康视云) - BoKang Vision Cloud plans to list on the Hong Kong Stock Exchange on July 3, 2025, with an IPO market value of approximately 8.473 billion HKD [10] - The company focuses on developing ophthalmic biotechnologies, with two core products in clinical trials for treating pterygium and myopia [11] Group 4: Stand Robot (斯坦德机器人) - Stand Robot submitted its IPO application on June 23, 2025, aiming to become the first industrial embodiment intelligent robot stock [13] - The company is recognized as the fifth largest industrial mobile robot solution provider globally, with significant growth in overseas revenue [14] - From 2022 to 2024, Stand Robot's revenue grew from 96 million yuan to 251 million yuan, with a compound annual growth rate of 61.3% [14] Group 5: Megatech (镁伽科技) - Megatech submitted its IPO application on June 25, 2025, and is the largest domestic autonomous intelligent body supplier in China [17] - The company reported a revenue growth from 455 million yuan in 2022 to 930 million yuan in 2024, with a compound annual growth rate of 43.0% [18] Group 6: Yikong Intelligent Driving (易控智驾) - Yikong Intelligent Driving plans to list on the Hong Kong Stock Exchange on June 25, 2025, and is the largest provider of L4-level autonomous driving solutions in the mining sector [21] - The company achieved a revenue increase from 60 million yuan in 2022 to 986 million yuan in 2024, with a compound annual growth rate of 305.8% [22] Group 7: Weimai (微脉) - Weimai submitted its IPO application on June 27, 2025, focusing on AI-driven full-process management services in healthcare [24] - The company reported revenue growth from 512 million yuan in 2022 to 653 million yuan in 2024, with a gross margin increase from 17.2% to 19.9% [25] Group 8: Cloud Yinggu (云英谷) - Cloud Yinggu submitted its IPO application on June 26, 2025, and is the largest AMOLED display driver chip manufacturer in mainland China [28] - The company reported a revenue increase from 551 million yuan in 2022 to 891 million yuan in 2024 [30] Group 9: Chengtai Technology (承泰科技) - Chengtai Technology submitted its IPO application on June 23, 2025, and is the largest supplier of vehicle-mounted millimeter-wave radar in China [33] - The company achieved a revenue increase from 58 million yuan in 2022 to 348 million yuan in 2024, with a compound annual growth rate of 145.7% [33] Group 10: Siwei Zhili (四维智联) - Siwei Zhili submitted its IPO application on June 27, 2025, and is a leading provider of intelligent cockpit solutions in China [36] - The company reported revenue of 539 million yuan in 2022, with a slight decline in subsequent years [36] Group 11: Haima Cloud (海马云) - Haima Cloud submitted its IPO application on June 27, 2025, and is the largest GPUaaS provider for real-time cloud rendering in China [40] - The company reported revenue growth from 290 million yuan in 2022 to 520 million yuan in 2024, with a compound annual growth rate of 33.8% [41] Group 12: Jingze Biopharma (景泽生物) - Jingze Biopharma submitted its IPO application on June 27, 2025, focusing on reproductive and ophthalmic pharmaceuticals [44] - The company has raised 927 million yuan in funding and has a pre-IPO valuation of 3.09 billion yuan [45] Group 13: Immvira Bioscience (亦诺微医药) - Immvira Bioscience submitted its IPO application on June 25, 2025, focusing on oncolytic immunotherapy and engineered exosome therapy [47] - The company has a pre-IPO valuation of 485 million USD [48]

Group 1: Company Developments - Bolekan Vision Cloud-B has launched its IPO on the Hong Kong Stock Exchange, with approximately 60.58 million shares available for global sale at a price of HKD 10.10 per share, indicating the company's confidence in its value [1] - Stand Robot has submitted its listing application to the Hong Kong Stock Exchange, focusing on industrial intelligent mobile robot solutions, despite currently being in a loss-making position [2] - Chengtai Technology has filed its prospectus with the Hong Kong Stock Exchange, specializing in millimeter-wave radar products, with projected revenues increasing from 0.58 billion to 3.48 billion from 2022 to 2024 [4] Group 2: Financial Performance - China Wangwang reported revenues of approximately 23.51 billion for the fiscal year ending March 31, 2025, a slight decrease of 0.3% year-on-year, while profit attributable to equity holders increased by 8.6% to 4.34 billion [3]

Summary of Key Points Core Viewpoint The article provides an overview of the recent activities in the Hong Kong stock market, highlighting the number of companies that have submitted applications for listing, those that have passed the hearing, and details about their financial performance and market positions. Group 1: New Applications - A total of 19 companies submitted applications to the Hong Kong Stock Exchange from June 16 to June 22 [3] - New Hope Group (600803.SH) is the largest private natural gas company in China, with a market share of approximately 6.1% in 2024 [3] - Wolong Technology (002130.SZ) is the second-largest high-speed copper cable manufacturer globally, holding a 24.9% market share [4] - Beijing Geekplus Technology Co., Ltd. is the largest provider of AMR solutions globally, maintaining its leading position for six consecutive years [5] - Banu International Holdings is the largest hot pot brand in China by revenue, with a market share of 3.1% [6] - Hope Sea Inc. is the largest comprehensive electronic product import supply chain solution provider in China, with an import GMV of approximately RMB 34.8 billion in 2024 [7] - Guangzhou Shiyuan Electronic Technology Co., Ltd. ranks first in the Chinese market for interactive smart panels with a 25.0% market share [8] - Anmai Biotechnology Co., Ltd. ranks second globally in T-cell connector therapy, with total transaction values exceeding USD 2.1 billion [9] - Beijing Haizhi Technology Group focuses on industrial-grade AI solutions, ranking fifth in the Chinese market [10] - Suzhou Jiyi Technology Co., Ltd. ranks second in digital retail operations in China [11] - Drip Irrigation International Investment Co., Ltd. is the first global exchange group based on revenue-sharing models [12] - Zhaowei Electromechanical (003021.SZ) provides integrated micro-drive systems, with revenues projected to grow [13] - Meige Intelligent (002881.SZ) ranks fourth globally in wireless communication modules, holding a 6.4% market share [14] - Yuxin Technology (300674.SZ) is a leading fintech solution provider in China, with significant market shares in various sectors [15] - Shanghai Zhuoyue Ruixin Digital Technology Co., Ltd. ranks second in the digital education market for higher education in China [16] - Zhaoyi Innovation (603986.SH) is the second-largest NOR Flash provider globally, with an 18.5% market share [17] - Changchun Changguang Chenxin Microelectronics Co., Ltd. specializes in high-performance CMOS image sensors [18] - Weichai Lovol Smart Agriculture Technology Co., Ltd. is a leading provider of smart agricultural solutions in China [19] - PPIO is an independent distributed cloud computing service provider [20] - Xiangkang Holdings is a major technical apparel manufacturer for high-end brands [22] Group 2: Companies Passing Hearings - Four companies passed the listing hearing this week, including Fuwai Group, which is a pan-Asian life insurance company with projected insurance revenue growth [24] - Fengcai Technology focuses on chip design for BLDC motor control, ranking sixth in the Chinese market [25] - Xunzhong Communication Technology Co., Ltd. is the third-largest cloud communication service provider in China [26] - Cloudbreak Pharma Inc. is a clinical-stage ophthalmic biotech company with two core products [27] Group 3: Recent IPOs - Haitan Flavor Industry (03288.HK) raised approximately HKD 10.1 billion in its IPO, with a slight decline in stock price post-listing [28] - Sanhua Intelligent (02050.HK) had a strong subscription rate for its IPO [29] - Baize Medical (02609.HK) and other companies also reported significant subscription rates for their IPOs [30][31][32][33]